PDS Biotechnology Corp (STU:EU6)

Q1 2026 PDS Biotechnology Corp Earnings Call Transcript

May 13, 2026 / 12:00 PM GMT

Release Date Price: €1.14 (+4.11%)

Transcript 10-Q8-K

Key Points

Positve

PDS Biotechnology Corp (PDSB) has made significant progress in advancing its clinical programs, particularly with the Versatile 003 trial amendment to incorporate progression-free survival as an interim primary endpoint.
The amendment to the Versatile 003 trial may shorten the trial's duration and reduce overall costs, potentially accelerating the availability of treatment for HPV-16 positive patients.
PDS0101, in combination with Keytruda, is the only late-stage investigational therapy for head and neck squamous cell carcinoma that requires only five doses and is administered subcutaneously.
PDS Biotechnology Corp (PDSB) strengthened its intellectual property portfolio with new patents in the United States and Japan, extending market protection into the 2040s.
The company reported promising results from ongoing trials for prostate and colorectal cancer with PDS01ADC, enhancing the efficacy of existing therapies across multiple solid tumor types.

Negative

PDS Biotechnology Corp (PDSB) reported a net loss of approximately $7.3 million for the quarter ended March 31, 2026.
Research and development expenses decreased to $3.5 million from $5.8 million in the prior year, primarily due to lower clinical and manufacturing costs, which may indicate reduced activity or investment in these areas.
General administrative expenses were slightly lower at $3.1 million compared to $3.3 million in the prior year, reflecting reduced professional fees.
The company's cash balance as of March 31, 2026, was $21.7 million, which may limit its ability to fund extensive future research and development activities without additional financing.
The landscape for HPV-16 positive head and neck cancer remains competitive, with BioNTech also conducting a phase three trial, posing potential challenges for PDS Biotechnology Corp (PDSB) in securing market share.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PDSB.OQ - PDS Biotechnology Corp
Q1 2026 PDS Biotechnology Corp Earnings Call
May 13, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance, please press *0 on your telephone keypad.

It is now my pleasure to introduce your host, Dean Schwartz.

Thank you. May begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator.

Good morning, everyone, and welcome to PDS Biotech's First Quarter 2026 Results and Clinical Programs

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.